Effect of alirocumab added to high-intensity statin therapy on coronary atherosclerosis in patients with acute myocardial infarction. The PACMAN-AMI randomized clinical trial.

Washington Heart Monitor

Please login to access the CRTOnline Presentations.
Effect of alirocumab added to high-intensity statin therapy on coronary atherosclerosis in patients with acute myocardial infarction. The PACMAN-AMI randomized clinical trial.

Posted: 07/31/2022
Author:
Michael Mahmoudi, MD - L Raber, et al.; JAMA 2022; 327:1771-81
2022 Journal Watch

Effect of alirocumab added to high-intensity statin therapy on coronary atherosclerosis in patients with acute myocardial infarction. The PACMAN-AMI randomized clinical trial.

Explore the Site

Stay Connected

CRT Group Foundation is a not for profit corporation dedicated to providing educational services in the field of cardiology through the website, CRTonline.org and the Cardiovascular Research Technologies (CRT) annual symposium. CRT focuses on the advances and changes in the field of cardiovascular medicine. CRT is designed to provide access to the world’s leading clinicians and the latest research in order to improve practice and treatment outcomes for a variety of health care professionals.

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Review our Privacy Policy for more details

Washington Heart Monitor

Effect of alirocumab added to high-intensity statin therapy on coronary atherosclerosis in patients with acute myocardial infarction. The PACMAN-AMI randomized clinical trial.

Explore the Site

Stay Connected